What is it about?
There is debate on whether the beneficial effect of implantable cardioverter-defibrillators (ICDs) is attenuated in patients with non-ischaemic cardiomyopathy (NICM). We assess whether any ICD benefit differs between patients with NICM and those with ischaemic cardiomyopathy (ICM)
Featured Image
Why is it important?
While Modern medical therapy has improved the outcomes of HF patients, beneficial effect of ICD has not investigated in modern medicine era, i.e. the era the optimal medical therapy has treated as standard and mandatory therapy for patients with HF.
Perspectives
The presence of ICD is associated with a survival benefit in patients with ICM but not in those with NICM.
Dr Tetz Cheng-Che Lee
Columbia University
Read the Original
This page is a summary of: Association between mortality and implantable cardioverter-defibrillators by aetiology of heart failure: a propensity-matched analysis of the WARCEF trial, ESC Heart Failure, February 2019, Wiley,
DOI: 10.1002/ehf2.12407.
You can read the full text:
Contributors
The following have contributed to this page
